Prostate cancer isn’t a single disease. It comes in several forms, and understanding which type you’re dealing with shapes everything from prognosis to treatment. The four types most commonly referenced are acinar adenocarcinoma, ductal adenocarcinoma, small cell (neuroendocrine) carcinoma, and transitional cell (urothelial) carcinoma. Of these, acinar adenocarcinoma is overwhelmingly the most common, and all other types are considered rare.
Acinar Adenocarcinoma
When people talk about prostate cancer without specifying a type, they almost always mean acinar adenocarcinoma. It accounts for the vast majority of all prostate cancer diagnoses. This type develops in the gland cells that line the small, rounded sacs (acini) of the prostate, the same cells responsible for producing the fluid component of semen.
Acinar adenocarcinoma typically causes elevated PSA levels, which is why routine PSA blood tests are effective at catching it early. It ranges widely in aggressiveness. Some tumors grow so slowly that active surveillance (monitoring without immediate treatment) is a safe choice, while others are fast-moving and require surgery, radiation, or hormone therapy. The specific behavior of a given tumor is captured by its grade, which doctors determine by examining biopsy tissue under a microscope.
Grading uses a system of five Grade Groups, developed from a study of more than 20,000 cases and now accepted by the World Health Organization. Grade Group 1 describes cancer made up entirely of well-formed glands, the least aggressive pattern. Grade Group 5 describes tissue that has lost its glandular structure almost entirely, indicating the most aggressive disease. You may also hear about the Gleason score, which is an older system still reported alongside the newer Grade Groups. A Gleason score of 6 corresponds to Grade Group 1, while scores of 9 or 10 correspond to Grade Group 5.
Ductal Adenocarcinoma
Ductal adenocarcinoma also originates in gland cells, but it starts in the tube-like ducts of the prostate rather than the rounded sacs. It is rare and classified as an aggressive type. Like acinar adenocarcinoma, it often raises PSA levels, so it can be picked up through standard screening. The similarity ends there.
Population-level studies show that ductal carcinoma behaves significantly worse than acinar adenocarcinoma at every stage. Among patients with non-metastatic disease, ductal carcinoma carries a 1.8 times higher rate of cancer-specific death compared to acinar. For patients who underwent surgery for non-metastatic disease, that gap widens to 2.8 times higher. Even after the cancer has spread, ductal carcinoma remains more lethal, with a 1.6-fold increase in cancer-specific death over metastatic acinar adenocarcinoma. Because it is uncommon, ductal adenocarcinoma is sometimes found mixed with acinar adenocarcinoma in the same biopsy specimen, which can complicate grading.
Small Cell (Neuroendocrine) Carcinoma
Small cell neuroendocrine carcinoma makes up less than 1% of all prostate cancers, but it is one of the most dangerous forms. It arises from neuroendocrine cells in the prostate, a different cell lineage than the gland cells that produce the adenocarcinomas described above. This distinction matters because it changes how the cancer behaves and how it responds to treatment.
The most important thing to know about small cell prostate cancer is that it typically does not raise PSA levels. That makes it invisible to standard PSA screening, and diagnoses are often delayed. Patients may present with severe urinary symptoms and rapid disease progression before anyone suspects cancer. Because PSA looks normal, the cancer can be misattributed to a non-cancerous condition. Small cell carcinoma also tends to resist hormone-based therapies that work well against adenocarcinomas, since its growth isn’t driven by testosterone in the same way. Treatment usually involves chemotherapy regimens similar to those used for small cell lung cancer.
Small cell neuroendocrine carcinoma can appear on its own (called “de novo”) or it can develop as a transformation from a previously treated adenocarcinoma, particularly after prolonged hormone therapy. Either way, it carries a poor prognosis and requires an aggressive treatment approach.
Transitional Cell (Urothelial) Carcinoma
Transitional cell carcinoma of the prostate starts in the urothelial cells lining the prostatic urethra, the tube that runs through the center of the gland. These are the same type of cells that line the bladder, and transitional cell carcinoma of the prostate is closely related to bladder cancer in both biology and treatment. In fact, it sometimes represents a direct extension of bladder cancer into the prostate rather than a cancer that originated there independently.
This type is rare. Because it arises from a completely different cell type than adenocarcinoma, it does not respond to the hormone therapies commonly used for prostate cancer. Treatment approaches tend to mirror those used for urothelial cancers elsewhere in the urinary tract, primarily chemotherapy and surgery. Like small cell carcinoma, transitional cell carcinoma may not produce significant PSA elevations, which can delay diagnosis.
Why the Type Matters for Treatment
Standard prostate cancer treatment is built around acinar adenocarcinoma. For early-stage disease (Stage I and II), options include active surveillance, surgery to remove the prostate, or radiation. As the stage increases, hormone therapy becomes a central part of the plan, often combined with radiation. At Stage IV, treatment shifts toward managing the disease with hormones, chemotherapy, and palliative measures to control symptoms.
These standard pathways assume the cancer responds to hormones, which is true for adenocarcinomas but often not true for small cell or transitional cell types. That’s why an accurate pathological diagnosis, not just a PSA number, is critical. A biopsy tells you what kind of cells you’re dealing with. If the cells are neuroendocrine or urothelial rather than glandular, the entire treatment strategy changes.
Ductal adenocarcinoma is treated similarly to acinar adenocarcinoma (surgery, radiation, hormone therapy), but its more aggressive nature means doctors may recommend earlier or more intensive intervention than they would for a low-grade acinar tumor. The higher mortality rates associated with ductal carcinoma at every stage reinforce the importance of close monitoring and prompt treatment decisions.
How These Types Are Identified
All four types are diagnosed through a tissue biopsy, typically guided by ultrasound or MRI. A pathologist examines the cells under a microscope and determines the histological type based on cell shape, growth pattern, and which part of the prostate the cancer originated from. Gland-forming cells point to acinar or ductal adenocarcinoma. Cells with neuroendocrine features indicate small cell carcinoma. Cells resembling the bladder lining indicate transitional cell carcinoma.
PSA testing is a useful first step, but it has blind spots. Acinar and ductal adenocarcinomas often elevate PSA, making them detectable through routine bloodwork. Small cell and transitional cell carcinomas frequently do not, which means a normal PSA result doesn’t rule out prostate cancer entirely. If you have significant urinary symptoms or other warning signs, imaging and biopsy may still be warranted regardless of your PSA level.